Download presentation
Presentation is loading. Please wait.
1
Vocabulary of Neoplasia
General Pathology C T. Davis
2
Metaplasia METAPLASIA is a reversible change in which one adult cell type is replaced by another adult cell type. Note: the influence that predisposes to change, if persistent, may induce cancer transformation in the metaplastic epithelium. Examples: Columnar-to-squamous (lung, cervix) Squamous-to-columnar (esophagus)
3
Endocervix with squamous metaplasia
4
Normal esophagus
5
Barrett Syndrome
6
Barrett’s syndrome
7
Glandular metaplasia
8
Adenocarcinoma
9
Dysplasia Term describing cells that have undergone proliferation and atypical cytologic alterations involving cell size, shape, and organization. In models of neoplasia in many organs dysplasia is an antecedent of malignancy (both in-situ cancers and invasive tumors).
12
Moderate dysplasia (dysplasia)
13
Carcinoma in-situ (CIS)
A preinvasive stage of epithelial malignancy which exhibits the cytologic features of malignancy but has not yet invaded beyond the confines of the native basement membrane.
14
Carcinoma In Situ of cervix (CIN III)
15
Carcinoma In Situ- mitoses throughout the epithelium
16
Early invasion by squamous cell carcinoma through the basement membrane
17
Pap Smears Normal Low Grade Moderate Severe/CIS
18
Definitions Neoplasia [G. neos, new + G. plasis, a molding]
- The pathologic process that results in the forrmation and growth of a neoplasm. “Abnormal growth that continues”
19
Neoplasm [neo- + G. plasma, thing formed]
“A neoplasm is an abnormal mass of tissue, the growth of which exceeds and is uncoordinated with that of the normal tissues and persists in the same excessive manner after cessation of the stimuli which evoked the change.” Sir Rupert Willis
20
-OMA(S) [Greek suffix ‘-oma’ = tumor]
Examples of benign tumors: lipoma, fibroma, angioma, leiomyoma, rhabdomyoma, Schwannoma, neuroma, hepatoma
21
Adenoma [G. aden, gland + -oma]
A term applied to benign epithelial neoplasms that form glands, as well as to the tumors derived from glands but not necessarily reproducing glandular patterns. Examples: cystadenoma, papillary cystadenoma, fibroadenoma
22
Malignant Neoplasms with “oma”
Carcinoma Sarcoma Lymphoma Melanoma Mesothelioma Glioma
23
And: teratoma Tumor with components from 2 or 3 germ cell layers
Ovary- usually benign Testis- usually malignant (in adults)
24
Ovarian Teratoma (“dermoid cyst”
25
Arrow indicates neural tissue; benign here, but sometimes malignant
26
Testicular teratoma
27
Tumors of Mesenchymal Origin
BENIGN Fibroma Lipoma Osteoma MALIGNANT (sarcomas) Fibrosarcoma Liposarcoma Osteosarcoma (osteogenic sarcoma)
29
Tumors of Muscle Origin
BENIGN Leiomyoma Rhabdomyoma MALIGNANT Leiomyosarcoma Rhabdomyosarcoma
30
Smooth muscle tumors of the myometrium
33
Benign smooth muscle of a leiomyoma
34
Tumors of Epithelial Origin (Carcinomas)
BENIGN Squamous cell papilloma Adenoma Tubular adenoma (adenomatous polyp) Fibroadenoma- breast MALIGNANT Squamous cell carcinoma Adenocarcinoma Colon carcinoma (adenocarcinoma) Adenocarcinoma, (Ductal carcinoma)
35
Multiple adenomatous polyps
36
Adenocarcinoma of colon
37
Invasive adenocarcinoma of colon
38
Anaplasia Anaplasia = Lack of differentiation = undifferentiated
Anaplasia is considered a hallmark of malignant transformation. Anaplastic features include: - Cellular/nuclear pleomorphism - Increased nuclear-cytoplasmic (N/C) ratio - Nuclear hyperchromasia (increased DNA content) - Large nucleoli
39
Anaplastic rhabdomyosarcoma
40
Generally, all benign tumors are well-differentiated
Malignant neoplasms, in contrast, range from well-differentiated to undifferentiated Well, moderately well, and undifferentiated (poorly differentiated or anaplastic) Grade 1, 2, or 3 (or I, II, III) with 3 the least differentiated)
41
Other Histologic Features of Malignant Neoplasms
Increased/atypical mitotic activity Tumor giant cells Abnormal architecture- sheets or masses of tumor cells growing in an anarchic, disorganized fashion with infiltration and destruction of normal tissues.
42
Anaplastic tumor with tripolar mitosis
43
Carcinoma Malignant neoplasms of epithelial cell origin, derived from any of the three germ layers, are called carcinomas. Examples of modifiers include: Squamous cell carcinoma, Adenocarcinoma, Renal cell carcinoma
44
Bronchogenic CA
45
Arrow indicates keratin “pearl”
46
SP SP Squamous cell carcinoma with “squamous pearls” (SP)
47
* * Intercellular bridges (*)
48
Pap Stain on sputum cytology: keratinized squamous cell carcinoma
49
Metastatic adenocarcinoma: immunohistochemistry + for thyroid
50
Sarcoma Cancers arising within mesenchymal tissue are called sarcomas.
Examples of modifiers include: - leiomyosarcoma - osteosarcoma - fibrosarcoma
52
Osteogenic Sarcoma (osteosarcoma)
53
Differentiation Differentiation refers to the extent to which parenchymal cells resemble comparable normal cells, both morphologically and functionally.
54
Differentiation and Tissue of Origin
A general rule is that neoplasms differentiate in the direction of their ‘parent’ tissue. - Consider: Transitional cell carcinoma of the urinary bladder is more common than squamous cell carcinoma and adenocarcinoma in this site. Conversely, transitional cell carcinoma arising in the ovary and uterine cervix is quite unusual, though may occur.
55
Liposarcoma
57
Additional Concepts Rate of Growth
In general, the growth rate of tumors correlates with their level of diffferentiation, and thus most malignant tumors grow more rapidly than do benign lesions. High grade malignant tumors (Grade 3) are more aggressive Local Invasion Most benign tumors are well circumscribed, while cancers grow by progressive infiltration, invasion, and destruction of the surrounding tissue.
58
GRADING TUMORS Malignant tumors only
Degree of differentiation and mitotic rate Grades I-IV (higher grades are more anaplastic) Important for some tumors: breast, prostate, endometrium, astocytomas Dysplasias of the cervix are “graded” Grading is done by Pathologists
59
STAGING TUMORS How far has the tumor spread? Malignant tumors only
Based on tumor size (T), lymph node involvement (N), distant metastases (M) Staging often involves: the Pathologist, radiology or other imaging, lab tests (tumor markers) CIS is often referred to as Stage Zero
60
Pathways of Spread Seeding of Body Cavities and Surfaces: carcinoma, mesothelioma, and thymoma Lymphatic Spread: initial route of spread for carcinomas Hematogenous Spread: utilized by sarcomas and carcinomas
61
Fibroadenoma of Breast
Benign; rubbery, well-demarcated No invasion No metastasis
62
Fibroadenoma
63
Benign ducts of a fibroadenoma
64
FIBROADENOMA Benign ducts of fibroadenoma
65
Ductal Carcinoma In Situ DCIS
66
DCIS (Ductal Carcinoma In Situ)
Surgery Meds. Watch Invasive (10 yrs.) % % % Die Brest CA (10 yrs.) % 2% %
67
DCIS- “A Rose is Not a Rose”
400 “Healthy” Women Surveyed for choice of treatment if DIAGNOSIS IS “DCIS” but other term used “non-invasive breast CA”- 53%: no surgery “Breast lesion” %: no surgery “Abnormal cells”- 69%: no surgery
68
Invasive
69
Invasive Ductal Carcinoma
Mammogram with carcinoma
70
Vascular invasion by invasive ductal carcinoma
71
BREAST CARCINOMA GRADING
Bloom and Richardson Tubules present (1-3 points) Nuclear atypia (1-3 points) Mitoses (1-3 points) Total score 3-5: Grade I (Well differentiated) Total score 6,7: Grade II (Moderately differentiated) Total score 8,9: Grade III (Poorly differentiated)
72
Well differentiated: Tubules Small nuclei (Well Diff.)
73
Moderately differentiated:
Rare tubules/solid nests Pleomorphic nuclei (Mod. Diff.)
74
Poorly differentiated:
No tubules; pleomorphic Many mitoses (Poorly Diff.)
75
BREAST CARCINOMA STAGING
Stage 0 (in situ or CIS): 5-year 92% Stage I. (<2 cm & LN-): 5-year 87% Stage II. (2-5 cm & 0-3 LN+): 5-year 75% *Stage III. (>5 cm & >4 LN+): 5-year 46% Stage IV. Distant metastases: 5-year 13%
76
BREAST CARCINOMA OTHER
Estrogen receptor (+): tumor is stimulated by estrogen and can be treated with the “anti-estrogen” tamoxifen. This is palliation. HER-2 Neu amplification: by immunostaining or FISH is seen in 20% of cases. If HER-2 Neu is amplified in the invasive tumor, the patient can be treated with Herceptin (Trastuzumab) or Tykerb (Lapatinib) . This is very expensive and tends to be used in high grade/high stage lesions that are HER-2 Neu positive. Triple Negative Breast Carcinoma- negative for estrogen and progesterone recptors and no overexpression of HER-2-Neu (recently reviewed in NEJM 363: )
77
ER (+)
78
HER-2 Neu (+)
79
COLON CANCER Grading is not very helpful
STAGING: predicts clinical outcome (TNM) No penetration of the muscularis mucosa (Tis); 100% cure rate Penetration of muscularis propria (and maybe serosa too) but lymph nodes negative (T3); 70% cure rate 1-3 (+) lymph nodes (N1); 30% cure rate Distant metastases (M1); rare cures
80
COLON CANCER OTHER 50% of colorectal carcinomas show “ras” mutations; 50% of adenomas > 1cm also show ras mutations CEA (carcinoembryonic Ag) can be used to follow patients after surgery Deeply infiltrating tumors cause desmoplasia (fibrosis) and “apple core/ napkin-ring” appearance. Desmoplasia is also seen in breast carcinoma
81
Adenomatous polyps
82
Adenoma: Crowded glands but no atypia
84
Molecular model for colorectal adenocarcinoma
85
TNM Staging System
86
Colon adenocarcinoma
87
Metastases: Metastases
are tumor implants discontinuous with the primary tumor. *METASTASIS unequivocally marks a tumor as malignant because benign neoplasms do not metastasize.
88
Liver with metastatic carcinoma
89
Metastatic melanoma in liver and bone marrow
90
2 additional Terms Choristoma: An ectopic rest of ‘normal’ tissue. Normal tissue in an abnormal location. Examples include glial tissue in the tongue, breast tissue in the “milk line”, nodules of pancreas in the small bowel, and adrenal rests in the uterine broad ligament or spermatic cord. Hamartoma: Mass of disorganized but mature specialized cells or tissue indigenous to the particular site. Hamartoma of lung is classically a mass of benign cartilage with or without, blood vessels, adipose tissue, etc. Hemangiomas are also called hamartomas.
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.